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Background: Up to 5% of inflammatory bowel disease (IBD) patients are thought to have 
clinically significant liver disease due to multifactorial causes, however, this figure may be an 
underestimate due to reliance on abnormal liver tests (LTs) and/or liver biopsies. 
Aims: Our aim was to evaluate the prevalence of clinically significant liver disease in IBD 
patients as defined by an increased liver stiffness measurement (LSM) ≥8kPa using transient 
elastography (TE). 
Methods: 110 IBD patients, and 55 non-IBD control subjects, had their LSM recorded using 
FibroScan® (EchoSense, Paris, France) by a single blinded operator trained in TE. 
Results: 71 Crohn's disease and 39 ulcerative colitis subjects were included. All demographic 
variables were similar between the IBD and control groups apart from a significantly higher 
proportion of IBD patients who smoked (17.3% vs 3.6%, P=0.013). Seven IBD patients 
(6.4%) had an LSM over 8kPa and 3 had persistently elevated LSMs 6 months later. One 
patient had compensated cirrhosis. No significant differences in overall LSM were observed 
between the IBD and control groups. Increased BMI and age, however, were independently 
associated with a higher LSM in the IBD but not in the control group (P<0.001 and 0.010 
respectively).  
Conclusion:  Using TE, the prevalence of clinically significant liver disease in IBD patients 
is low. The association of increased BMI and age with increased LSM in IBD suggests fatty 
liver disease being the prevailing aetiology in these patients.  
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Introduction. 
Hepatobiliary disease is one of the most common extra-intestinal manifestations of 
inflammatory bowel disease (IBD) with the prevalence of deranged liver biochemistry in 
these patients ranging between 3 and 50%.1,2  These changes may be transient or related to 
IBD activity,1,3 fatty liver disease,4 primary sclerosing cholangitis (PSC),4 medications 
(thiopurines and methotrexate), nodular regenerative hyperplasia,5,6 autoimmune hepatitis,7 
and cholelithiasis.7 Another concern is that the use, and then the withdrawal, of 
immunosuppressive medications may result in flaring of pre-existing chronic hepatitis B,8 
while the use of corticosteroids may promote the development of, or exacerbate, underlying 
non-alcoholic fatty liver disease (NAFLD). Finally, the anti-TNFα agents, whist efficacious 
in combating gut mucosal inflammation, are hepatotoxic in some patients.9 
 
It is estimated that approximately 5% of adult patients with IBD will develop clinically 
significant liver disease,10 but a far larger proportion of patients will be noted as having 
abnormal liver biochemistries. The reliance on abnormal liver biochemistry to demonstrate 
liver injury, however, is flawed as the degree of biochemical derangement does not always 
correlate with the extent of liver injury and thus may result in either an over, or 
underestimation of the injury if used on its own.11-13 The addition of liver biopsies in these 
patients will improve the assessment of the liver, but are subject to sampling errors and are 
usually only performed in patients with markedly deranged liver tests. Patient acceptance of 
this test is often poor due to its invasiveness, pain and risk of morbidity. Thus, the true 
prevalence of clinically significant chronic liver disease in patients with IBD is not known 
and could be underestimated. 
 
Transient elastography (TE) is a technique that utilises sound waves to assess liver stiffness. 
Liver stiffness measurements (LSMs) can be used to predict hepatic fibrosis and have been 
validated in patients with chronic hepatitis C where they are noted to be accurate predictors 
of advanced fibrosis and cirrhosis.14 This test is non-invasive, reproducible and not subject to 
the same sampling errors that can affect liver biopsies.  More recently, TE was demonstrated 
to be accurate in detecting significant fibrosis (perisinusoidal and portal/ periportal fibrosis, 
Metavir F2), advance fibrosis (septal or bridging fibrosis, Metavir F3) and cirrhosis (Metavir 
F4) in patients with NAFLD with area under receiver operator characteristic curve values of 
0.84, 0.92 and 0.97 respectively.15 Its use has also been studied in cholestatic liver diseases14 
and patients treated with methotrexate.16,17 The aim of this prospective study was, therefore, 
to identify the LSM characteristics of a cohort of IBD patients using FibroScan® (Echosense, 
Paris France), the prevalence of clinically significant liver disease in this IBD cohort, and 
whether there are differences between the LSMs of the IBD  and a non-IBD control group.  
 
Methods 
Study design and subjects 
This was an observational prospective, cross-sectional study that recruited consecutive, 
consenting IBD patients between October 2011 and April 2012 from the Centre for 
Inflammatory Bowel Diseases, Fremantle Hospital, a specialised IBD unit. The study was 
reviewed and approved by the South Metropolitan Area Health Services Human Research 
Ethics Committee.  All patients were 18 years or older with a diagnosis of IBD based on 
established clinical, endoscopic, radiological and histological criteria, and gave written 
informed consent prior to inclusion.  Patient clinical details were collected including body 
mass index (BMI), history of diabetes mellitus, number of standard alcoholic drinks per 
week, smoking history, history of liver disease, Montreal classification, disease duration, 
current medications and IBD activity score at the time of the TE reading (Harvey Bradshaw 
Index (HBI), or partial Mayo score, for CD and UC respectively). Liver function tests were 
assessed within 1 month of the TE reading and all patients had their viral hepatitis serology 
and vaccination status checked as part of their routine clinical care in the IBD clinic. Random 
volunteers that did not have IBD, which included hospital staff and patient relatives, served 
as controls and had their TE readings compared with the IBD group. The ratio of non- IBD 
control to IBD subjects was 1:2. 
 
Transient elastography.  
 
The LSMs on all patients were performed by a single research nurse trained in TE using the 
FibroScan® (Echosens, Paris, France).  LSMs were performed with the patient lying in the 
dorsal decubitus position with the right arm in maximal abduction. The tip of the transducer 
probe was covered with coupling gel and placed on the skin between the ribs at the level of 
the right lobe of the liver. A special obesity probe was used for subjects with a BMI greater 
than 30kg/m2. Only the results from subjects with 10 successful LSM acquisitions were 
included for analysis. The median value of these 10 readings represented the liver elastic 
modulus. The success rate was calculated by dividing the number of successful 
measurements by the total number of measurements; only those with a success rate of at least 
60% were included in the study, as previously described.14  The operator was blinded to the 
patients’ clinical information.  
 
Definitions 
Based on prior experience in hepatitis C patients, a TE reading of greater than 8kPa was 
considered to represent a clinically significant level of fibrosis (≥F2 on the Metavir scale).14 
The definitions for liver injury were derived from the International Consensus meeting 
recommendations organised under the auspices of the Council for International Organisations 
of Medical Sciences (CIOMS).18 “Abnormality of liver tests (LT)” was defined as an increase 
in AST, ALT, ALP, GGT or total bilirubin between N (upper limit of normal range) and 2N. 
“Liver injury” or “hepatotoxicity” was defined as an increase of over 2N in ALT. “Marked 
liver injury/ severe hepatotoxicity” was considered if the transaminases were greater than 5N.   
 
Those patients with LTs >2N, or TE readings greater than 8kPa, were assessed for 
autoimmune (anti- smooth muscle antibody, anti- liver-kidney microsomal antibody, 
immunoglobulins, anti- mitochondrial antibody), viral (hepatitis B and C serology) and 
metabolic (caeruloplasmin, iron studies, alpha-1 antitrypsin deficiency) causes along with a 
hepato-biliary ultrasound. TE and LTs in these patients were then repeated 6 months after the 
first abnormal reading and if these were persistently abnormal, the patients were referred for 
hepatology review and consideration of a liver biopsy. Control subjects who were noted to 
have abnormal results were followed in a similar manner. 
 
Statistical methods 
Statistical tests were performed using Statistical Package for Social Sciences version 16 and 
STATA version 12.   Due to non-normality and a tendency towards large differences in the 
variance of the continuous variables in this study (age, BMI, LSM and number of standard 
alcoholic drinks per week) the medians and interquartile range were used to summarise the 
central tendency by IBD group, although means and t-test p-values were also calculated. 
Categorical variables were summarized as proportions. Non-parametric Mann-Whitney U 
tests were performed to compare control and IBD group differences between continuous 
variables and chi-square test or Fisher’s exact test (when expected values < 5) on categorical 
variables. All statistical tests were two sided with a significance level of 0.05.  
 
Multi-variable regression models were used to find factors associated with increased LSM 
values.  Initially standard linear regression models were assessed but normality and constant 
variance (heteroscedasticity) assumptions were violated at the higher LSM values.  A log 
transformation of the LSM values reduced these problems and to avoid having to back-
transform coefficients, generalized linear models using a log link and Gaussian distribution 
were used to investigate the association.  Purposeful backward stepwise model building 
involved including all variables with p-values ≤0.25 in univariate analyses and then removing 
variables one at a time until only those remaining had p<0.05.  Plausible interaction terms 
were then tested amongst remaining and any dropped variables.   Robust standard errors were 
used to account for any remaining heteroscedasticity. 
 
Results 
A total of 114 IBD patients and 59 non-IBD control patients underwent TE. 4 IBD patients 
(3.6%) and 4 non-IBD control subjects (7.2%) were subsequently excluded due to 
unsuccessful TE acquisitions. The baseline demographical and disease characteristics are 
presented in Table 1 and Table 2 respectively.  There were no significant differences in the 
baseline characteristics between the two groups apart from a greater proportion of current 
cigarette smokers (>1 cigarette/day) in the IBD group compared to the control group (17.3% 
vs 3.6%, P=0.013). There was a tendency towards the IBD group to have a higher BMI but 
this was not statistically significant. 
 
Of the IBD group, approximately two thirds were Crohn’s disease (CD) patients (Table 2). 
The mean duration of disease in the IBD group overall was 12 years and the majority were on 
an immunosuppressing medication; azathioprine/ 6-MP (40.9%), methotrexate (1.8%), 
tacrolimus (2.7%)) or an anti-TNFα medication (infliximab; 7.3%, adalimumab; 18.2%). 75% 
of CD patients and 79.5% of UC patients were in remission at the time the TE reading was 
taken, defined as a HBI of ≤4 and partial Mayo score of ≤2 respectively. The mean HBI score 
in CD patients was 2.7 ± 4.1, and partial mayo score in UC patients was 1.4 ± 2.4. 
 
No patients in the control group had a history of liver disease, while 5 IBD patients had a 
known history, 3 with NAFLD and 2 with PSC. Of these 5 patients, 1 patient with NAFLD 
had an abnormal TE reading (8.6kPa) and normal LTs while 1 patient with PSC had 
cholestatic LTs and a normal TE reading. The other 3 patients had normal TE readings and 
LTs. There were 2 IBD patients that were taking methotrexate and had normal LTs and TE 
readings. 
 
Difference in LSM between IBD and control groups 
There was no statistically significant difference in the median LSM values between the 
control and IBD groups (4.5kPa; IQR 3.9-5.6kPa vs 4.7kPA; IQR 4-6kPa, P=0.626 Table 1). 
7 IBD patients (6.4%) had a TE reading ≥8kPa compared to none of the controls.  All 7 
patients had normal LTs, normal autoimmune, viral and metabolic blood tests for 
hepatological workup and two had sonographic features of a fatty liver.  3 of the 7 patients 
had persistently elevated TE readings when rechecked six months later and this was 
associated with weight gain (Table 3), while the other 4 had normalised their LSMs and this 
was accompanied by weight loss. One of the patients with a persistently elevated TE reading 
of 12.1kPa (Table 3, case #7) was considered to have compensated cirrhosis with a low 
platelet count, coarsened echo texture and splenomegaly on ultrasound.  This patient was 
referred to hepatology clinic for review, however no liver biopsy has been undertaken due to 
poor patient acceptance of the procedural risks and the likelihood of NAFLD/NASH being 
the underlying cause.  
 
Interaction between LSM, age and BMI in IBD vs non-IBD control groups. 
Further investigation demonstrated that while the overall LSM values were similar in both 
groups, LSM values within the control and IBD groups varied significantly with age and 
BMI.  Regression analyses identified an association between increased LSM and IBD that 
was modified by patient age and BMI (Table 4).   There was a trend of an increase in mean 
LSM with increasing age but only in patients with IBD.  IBD patients aged ≥60 years had a 
mean LSM 2.1 kPa higher than IBD patients aged <40 years.  In contrast, there was no 
increase in mean LSM with age in the control group; instead there was some evidence of 
small decrease in mean LSM with increasing age. The association of LSM with IBD was also 
modified by patient BMI.   An increase in BMI was associated with an increased mean LSM 
value in IBD patients. IBD patients with a BMI >30kg/m2 had mean LSM values 3.5 kPa 
higher than IBD patients of normal weight or lower.   There was no statistically significant 
effect of BMI on LSM values in the control group. 
 
Effect of anti-TNFα agents on LSM 
There were 28 patients (25.5%) in this study on an anti-TNFα medication.  After controlling 
for IBD, BMI and age, IBD patients who were being treated with an anti-TNFα agent had a 
lower mean LSM compared to those who were not (4.5 kPA, 95% CI 4.1-5.0 vs 5.2 kPa, 
95%CI 4.9-5.5; P=0.048).  There was no significant difference in the proportion of anti-
TNFα-treated IBD patients who were in disease remission (85.7% vs 73.2%, P=0.2), or on 
corticosteroid therapy (10.7% vs 14.6%, P=0.6) compared to those not on an anti-TNFα 
agent.  
 
Gender, diabetes status, IBD disease duration and disease activity, corticosteroid use, 
immunomodulator treatment, smoking, alcohol consumption and history of liver disease were 
not associated with significant differences in LSM values and were removed from the 
regression model.  
 
To investigate whether the observed association of IBD and LSM could be attributed to the 
underlying disease, a regression model that specified the IBD subtype as CD or UC was 
constructed.  A similar model with age and BMI interaction terms indicated that most of the 
observed increase in LSM with increasing BMI observed earlier in IBD patients was from 
CD patients (Table 5).  For the control group and for patients with UC there was no evidence 
in this study that increasing BMI was associated with higher LSMs.  As only a third of all 
IBD patients had UC however, this lack of an association could be the result of inadequate 
power.  There was evidence that the association of increasing LSM with increasing age in 
IBD patients was seen in both patients with UC and CD, however a larger study would be 
needed to confirm these trends. 
 
Patients with abnormal LT but normal LSMs. 
Four patients with normal LSMs had evidence of mild liver injury (LT> 2N), although none 
had LTs which exceeded 3N. The aetiologies given in the clinical history and after 
hepatological workup were, thiopurine metabolite shunting in 1 patient, excessive alcohol use 
in 1 patient and NAFLD/NASH in 2 patients. The thiopurine shunter had a 6MMP level of 
8470 pmol/8x108 RBC which decreased to <500 pmol/8x108 RBC accompanied by a 
normalisation of transaminases on addition of allopurinol. The other 3 patients had 
persistently elevated transaminases that were <2N on follow up and were advised to lose 
weight/ decrease alcohol use.   
 
Discussion. 
Few studies have explored the liver health of the IBD population using TE and the studies 
that are available, have examined only CD patients treated with methotrexate.13,16,19 These 
studies have shown that the prevalence of liver fibrosis from methotrexate itself is low and 
that the aetiology for any raised LT or TE reading is more likely due to NAFLD or excessive 
alcohol use.  As hepatobiliary complications in IBD patients are not uncommon and 
heterogeneous in aetiology, our aim in this study, was to characterise the LSM characteristics 
of a cohort of IBD patients and evaluate the prevalence of clinically significant liver disease 
from any cause as defined by a TE reading of ≥8 kPa.  . 
 
The definition of ‘significant fibrosis (Metavir F2)’ ‘advanced fibrosis’ (Metavir F3) and 
‘cirrhosis’ (Metavir F4) have been evaluated in many studies using FibroScan® (Echosense, 
Paris, France) with the findings most recognised in hepatitis C patients.  Work has also been 
performed on NAFLD/NASH patients which have demonstrated comparable accuracy that 
was not compromised by BMI or degree of steatosis.15 Cut off levels for each category of 
fibrosis is variable, however, most work performed on hepatitis C cases have shown that 
Metavir F2, F3 and F4 levels of fibrosis correspond to a TE values of 7.1-8.8kPa, 9.5-9.6 
kPa, and 12.5 to14.6 kPa respectively based on a comprehensive review.14 Accordingly, in 
this study clinically significant liver disease was defined as F2, which was to be a TE reading 
of ≥8 kPa. 
 
This study demonstrated no significant differences in the overall LSM between the IBD 
patients and controls.  The prevalence of clinically significant liver disease in IBD was noted 
to be low (6.4%) and the 7 patients were thought to have NAFLD following a normal 
hepatological work up, the presence of an elevated BMI and/or ultrasonographic findings of a 
fatty liver. Only 3 patients had a persistently elevated LSM after 6 months of follow-up 
associated with a corresponding weight gain with 1 patient that was suspected to having 
compensated cirrhosis.  The low numbers of IBD patients with potentially significant liver 
disease is reassuring and is consistent with what is known in the literature.10 
 
Although the LSMs of IBD patients did not significantly differ between IBD and control 
patients, a higher BMI and increased age were both significantly associated with a higher 
LSM in the IBD group, a finding that was not observed in the control group.  This lack of 
association in the control group may be due to the “healthy worker effect” as this group 
consisted of hospital staff such as medical students, doctors and nurses who may be healthier 
individuals that are not entirely representative of the general population from which similar 
trends probably exist.  The association between increased BMI and LSM in the IBD group 
combined with the results of the complete hepatological workup suggests that NAFLD is the 
likely underlying aetiology of the increased LSM.  Increased age being associated with higher 
LSMs may be explained by the higher likelihood of metabolic syndrome in older individuals, 
contributing to NALFD.  We did not, however, formally seek to identify or measure 
metabolic risk factors in this study apart from the presence of diabetes mellitus.  
 
The trend observed for an increased LSM in IBD patients with a higher BMI was only 
observed in the CD subgroup, but the reason may be due to an inadequate sample size of UC 
patients. It is, however, well-known that smoking plays an important role in CD and a 
significant proportion of our CD cohort smoked. This may predispose these patients to 
NAFLD as one study investigating a large cohort of NALFD patients demonstrated that a 
>10 smoking pack years was an independent predictor of progression to advance fibrosis, 
potentially mediated through an increase in insulin resistance.20   
One quarter of the total IBD group was on an anti-TNFα agent, which was associated with a 
lower LSM value. In this cohort, being on an anti-TNFα medication was not significantly 
associated with increased proportions of patients in disease remission, or on corticosteroid 
free regimens, which might have otherwise explained a lower risk of metabolic syndrome and 
NAFLD.  Cumulative corticosteroid dose however, which may have a stronger link with 
NAFLD, was not measured in this study and may be lower in those patients on an anti-TNFα 
agent due to better disease control. Another possible explanation lies in the potential 
biological effects of anti-TNFα agents on hepatic inflammation and fibrogenesis.  Although 
there have been documented hepatotoxic drug-induced, autoimmune like reactions9 from 
anti-TNFα medications, these agents have also been shown to improve necro-inflammatory 
changes in alcoholic hepatitis21 and in vitro models of NASH,22 due to the up regulation of 
TNFα in these disease processes. The possible protective value of anti-TNFα medications 
requires further investigation in larger studies. 
 
An additional potential limitation of the study might relate to the smaller sample size in 
subgroups which reduced the ability to explore any further relationships. A post-hoc power 
calculation indicated that this study would have had 90% power to detect a difference of 0.9 
in mean LSMs at a 0.05 significance level.  This study was, therefore, underpowered to detect 
small changes in mean LSM values that may have been present.  No liver biopsies were 
performed on any of the patients with either an elevated TE reading, repeated readings and/or 
those with abnormal LT’s.  Poor patient acceptability, lack of strength for an indication and 
lack of influence on clinical management were the reasons given to decline a liver biopsy. 
This did not detract, however, from achieving the aim of this study, which was to apply a 
validated modality liver fibrosis assessment on a group of IBD patients to characterise the 
LSMs in this group. 
In conclusion this study demonstrated that the prevalence of potentially clinically significant 
liver disease using TE, in an IBD population is low and that any prevailing liver abnormality 
is most likely secondary to NAFLD. Optimisation of metabolic risk factors, including 
emphasis on smoking cessation and minimisation of corticosteroid use, should continue to be 
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Table 1. Baseline demographic characteristics 
 IBD group (n=110) Control group (n=55)  
 median IQR median IQR p-value 
Age 42 30-55 40 26-55 NS 
BMIa 24.0 22.0-27.0 24.9 21.9-28.1 NS 
Standard drinks/week 1 0-7 2 0-5 NS 
LSMb 4.7 4.0-6.0 4.5 3.9-5.6 NS 
 n % n %  
Sex      
Male 52 47.3 28 50.9 
NS 
Female 58 52.7 27 49.1 
 
BMI category      
<25 56 50.9 32 58.2  
25-29 37 33.6 20 36.4 NS 
>=30 17 15.5 3 5.5  
 
Cigarette smokers      
No 91 82.7 53 96.4 
0.013 
Yes 19 17.3 2 3.6 
 
History liver disease      
No 105 95.4 55 100.0 
NS 
Yes 5 4.6 0 0.0 
 
Diabetes      
No 106 96.4 55 100.0 
NS 
Yes 4 3.6 0 0.0 










Table 2 Disease Characteristics of IBD patients. 
 
 CD 
n = 71 
UC 
n= 39 
Age  n= (%) 
A1  
A2 
A3                        














B3                       
 





































Disease duration mean yrs±SD 13±11 11±10 
Smokers n= (%) 18 (25.3) 1 (2.6) 












2   (2.8) 
0  





4b   (10.3) 






Mean Disease Activity scores (SD) 
CD (HBI) 
UC/IBDU (Partial Mayo) 
 




1.4 ± 2.4 
Proportion in remission at TE 
reading n= (%) 
53 (75) 31 (79.5) 
Abbreviations: HBI – Harvey Bradshaw index   a3 patients used rectal 5ASA  
b1 patient  used rectal steroids 
Table 3.  Cases with elevated LSM readings and repeat LSM reading with BMI taken 6 
months later. 








1 14.9 81 10 84 
2 21.1 87 6.4 80 
3 8.6 85 8.0 90 
4 10.2 122 6.5 110 
5 9.4 92 6.7 87 
6 8.6 74 6.4 75 
7 15.1 86 12.1 89 
 


















 ∆ mean LSM 95% CI p-value 
IBD status within BMI categories    
Control group     
<25 ref1 - - 
25-29 -0.33 -0.95 – 0.29 0.291 
>=30 -0.19 -0.91 – 0.54 0.614 
 IBD group    
<25 ref - - 
25-29 0.58 0.02 – 1.13 0.044 
>=30 3.48 1.49 – 5.46 0.001 
    
Age group within IBD status    
Control group    
<40 years ref - - 
40-60 years -0.26 -0.89 – 0.37 0.422 
>60 years -0.75 -0.01 - -0.08 0.028 
    
IBD group    
<40 years ref - - 
40-60 years 0.62 -0.01- 1.26 0.053 
>60 years 2.07 0.32 – 3.83 0.020 
    
Anti-TNF treatment    
No ref   









1Ref= Referent group.  
 
Table 4:  Factors associated with change in LSM values as estimated 






 ∆ mean LSM 95% CI p-value 
BMI category within IBD disease type    
Control group     
<25 ref - - 
25-29 -0.33 -0.95 – 0.29 0.291 
>=30 -0.19 -0.91 – 0.54 0.614 
Crohn’s disease     
<25 ref - - 
25-29 0.35 -0.59 – 1.28 0.467 
>=30 3.98 1.97 – 6.00 <0.001 
Ulcerative colitis     
<25 ref - - 
25-29 0.50 -0.38 – 1.38 0.268 
>=30 1.68 -0.57 – 3.94 0.143 
Age group within IBD disease type    
Control group     
<40 years ref - - 
40-60 years -0.26 -0.89 – 0.37 0.422 
>60 years -0.75 -1.41 - -0.08 0.028 
Crohn’s disease     
<40 years ref - - 
40-60 years 0.55 -0.47 – 1.57 0.292 
>60 years 2.77 0.70 – 4.84 0.009 
Ulcerative colitis     
<40 years ref - - 
40-60 years 0.96 0.04 -1.88 0.041 
>60 years 0.87 -0.98 – 2.42 0.247 
Anti-TNF treatment    
No ref   




Table 5.  Factors associated with change in mean LSM score with IBD 
categorised into specific disease type as estimated from a generalised linear 
model with robust standard errors. 
1Ref = referent group   
 
 
